| Astellas Seals the Deal With OSI After Rocky Courtship The Burrill Report submits: By Michael FitzhughAstellas Pharma (ALPMF.PK), Japan's second-largest drugmaker, is paying $4 billion for OSI Pharmecuticals (OSIP) and its profitable cancer medicine, Tarceva. The pricey victory is a triple-win for Astellas, likely to bolster its revenue, geographic base, and pipeline. Complete Story » seekingalpha.com |
FDA Details JNJ's Quality Issues New details emerged about quality-control issues at a Johnson & Johnson plant in Lancaster, Pa., the third to be cited by regulators in recent months. online.wsj.com |
Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript Poniard Pharmaceuticals, Inc. (PARD)Q2 2010 Earnings CallAugust 9, 2010 4:30 pm ETComplete Story » seekingalpha.com |
Cutting Cellphone Radiation There are a number of products designed to cut exposure to cellphone radiation. Scientists say some gadgets don't work, but others may be a reasonable precaution. Aches & Claims looks at the evidence. online.wsj.com |
Detecting More Upside Potential for EXACT Sciences Mike Havrilla submits:With shares of EXACT Sciences (EXAS) pulling back from multi-year highs in the low $9s back to the low-mid $7s as I write this article, I am adding to my long stock position ahead of the validation study results to be presented next week. (Click here for my recent article on the merger of my site with BioRunUp.com, providing investors and traders with more resources to profit from FDA and clinical trial binary events.)Next-Generation (V3), Stool DNA (sDNA) Based Colorectal Cancer (CRC) Diagnostic Test Kit Complete Story » seekingalpha.com |